Korro Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 1.49K shares, a 87.23% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 19.31K shares, a 67.10% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 7.14K shares, a 81.51% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 40.04K shares, a 64.08% decline from fiscal 2024.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 111.46K shares, a 182.93% increase from fiscal 2023.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 39.40K shares.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 769.38K shares, a 115.41% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 27.94K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 1.49K shares 10-Q · filed 2026-05-07 | 29.88K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 19.31K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 40.04K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 7.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 79.42K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 1.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 110.91K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 11.64K shares 10-Q · filed 2025-05-07 | 117.16K shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 58.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 111.46K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 38.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2024-06-30 | 8.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | |
| 2024-03-31 | 5.95K shares 10-Q · filed 2024-05-14 | |
| 2023-12-31 | 39.40K shares 10-K · filed 2024-03-26 | |
| 2021-03-31 | 697.00 shares 10-Q · filed 2022-05-04 | 605.34K shares derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | 231.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | 769.38K shares 10-K · filed 2021-03-29 |
| 2020-09-30 | 132.68K shares 10-Q · filed 2020-11-16 | 597.25K shares derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-06-30 | 240.25K shares 10-Q · filed 2020-08-12 | 542.60K shares derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-03-31 | 164.74K shares 10-Q · filed 2020-05-14 | 395.96K shares derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-12-31 | 59.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | 357.17K shares 10-K · filed 2021-03-29 |
| 2019-09-30 | 78.04K shares 10-Q · filed 2020-11-16 | 315.99K shares derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | 93.61K shares 10-Q · filed 2020-08-12 | 292.62K shares derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | 131.49K shares 10-Q · filed 2020-05-14 | |
| 2018-12-31 | 12.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | 126.25K shares 10-K · filed 2020-03-26 |
| 2018-09-30 | 54.67K shares 10-Q · filed 2019-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |